Johnson and Johnson subsidiary Ethicon will market Evicel.
Omrix Biopharmaceuticals Ltd. (Nasdaq:OMRI) has obtained US Food and Drug Administration (FDA) marketing approval for its liquid fibrin sealant, Evicel, in vascular surgery.
Until now, Evicel has only been approved for use in liver surgery. Omirx has now registered the product for use in abdominal surgery. When approval is obtained for the three indications, the company will be able to file applications to register the product for all types of surgical procedures.
Omrix says that Evicel is especially useful in cases where blood clotting by usual procedures is impossible or risky. Ethicon Inc. will market Evicel. Ethicon’s parent, Johnson and Johnson (NYSE:JNJ), is Omrix’s partner in the biological hemostats field.
Published by Globes [online], Israel business news - www.globes.co.il - on May 17, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007